库马林作为XIIa因子抑制剂:使用基于片段的策略来改善功效和选择性
Clara Davoine1, Amandine Traina2, Jonathan Evrard2
1Namur Medicine & Drug Innovation Center (NAMEDIC - NARILIS), University of Namur, Rue de Bruxelles 61, 5000, Namur, Belgium; Laboratory for the Analysis of Medicines (LAM), Department of Pharmacy, CIRM, University of Liege, Place Du 20 Août 7, 4000, Liège, Belgium.
研究人员开发了XIIa因子的强效纳米分子抑制剂,XIIa因子是血栓形成和炎症的关键标. 这种基于片段的方法显著改善了早期的弱库马林抑制剂,显示出治疗应用的前景.
科学领域:
- 药用化学 医学化学
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 因子XIIa是治疗血栓形成和炎症状况的重要点.
- 之前的研究已经确定了XIIa因子的弱库马林抑制剂.
研究的目的:
- 通过基于片段的药物发现方法来增强现有的XIIa因子的库马林抑制剂.
- 开发XIIa因子的强效和选择性抑制剂.
主要方法:
- 选了大约200个碎片,准了XIIa因子保存的S1口袋.
- 将活性片段与库马林模板合并,制造出新的抑制剂.
- 使用质谱测量研究了抑制机制,并在基于血的凝血试验中评估了化合物的疗效.
主要成果:
- 识别了具有微分子活性的碎片,并评估了它们与其他血清蛋白酶的选择性.
- 通过将碎片与库马林支架合并生成强大的纳米分子抑制剂.
- 通过乙酶复合体的形成证明了共价结合,并证实了良好的血稳定性 (1.9小时半衰期) 和内在凝固途径的选择性.
结论:
- 基于碎片的方法成功产生了显著改善的基于氨酸的XIIa因子抑制剂.
- 开发的抑制剂表现出有利的药理动力学特性和途径选择性,需要进一步研究血栓形成和炎症的治疗潜力.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Factors Affecting Protein-Drug Binding: Protein-Related Factors
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
Factors Affecting Protein-Drug Binding: Drug Interactions
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...


